Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05008549 · ClinicalTrials.gov registry record · NA
A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function
A NA study of Mood and Attention, sponsored by Ocean Spray Cranberries.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05008549: Completed NA study of Mood and Attention, sponsored by Ocean Spray Cranberries.
NCT05008549 is a NA study of Mood and Attention that has completed, run by Ocean Spray Cranberries. The registered enrollment target is 25 participants, below the 3,659-participant average among 29 other Mood trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05008549, a NA study of Mood and Attention, has completed, sponsored by Ocean Spray Cranberries.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to determine the effect short-term dosing (7 days) of a placebo beverage, cranberry juice, cranberry juice + lemon balm extract, cranberry juice + tart cherry powder, or cranberry juice + L-theanine or L-theanine beverage on cognitive function and mood in healthy adults (18-45 years). The study will include measures of attention, alertness, performance, and mood/stress.
Primary Outcome
Change in Accuracy of Attention and Change in Speed of Attention composite scores outcomes from Baseline to each treatment phase (V3-8), assessed using the COMPASS cognitive assessment tool.
Interventions
- DIETARY_SUPPLEMENT Cranberry Juice Product
Study Locations (1)
Illinois
- Atlantia Clinical Trials Ltd - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2021-11-01 |
| Phase | NA |
What the finished NCT05008549 record still lists
NCT05008549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 3,659-participant average among 29 other Mood trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Mood appearing as the primary indexed condition, and to 1 intervention - of which Cranberry Juice Product is the first listed.
NCT05008549 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05008549 about?
NCT05008549 is a clinical study titled "A Study to Assess the Synergistic Effects of a Cranberry Beverage on Cognitive Function". This study aims to determine the effect short-term dosing (7 days) of a placebo beverage, cranberry juice, cranberry juice + lemon balm extract, cranberry juice + tart cherry powder, or cranberry juice + L-theanine or L-theanine beverage on cognitive function and mood in healthy adults (18-45 years)...
What is the current status of trial NCT05008549?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2021-07-26. Estimated completion is 2021-11-01.
What conditions does trial NCT05008549 study?
This clinical trial studies the following conditions: Mood, Attention.
What interventions are being tested in trial NCT05008549?
The interventions under investigation include: Cranberry Juice Product (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05008549?
This trial is sponsored by Ocean Spray Cranberries, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05008549 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05008549's enrollment target sits among peer trials
25 25th of 29 higher than 3 of 29 other Mood trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mood trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Student Exercise and Sleep Timing Study - Part 2
RECRUITING · NA
-
Efficacy and Safety of Shatavari for Treatment of Menopausal Symptoms in Women: A Randomized, Double-blind, Three-arm, Parallel, Placebo-controlled Study
RECRUITING · NA
-
Developing Resilience and Anxiety Management Through the Arts
RECRUITING · NA
-
Impact of Bright Light Therapy on Prader-Willi Syndrome
RECRUITING · NA
-
Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health
RECRUITING · NA
-
Intern Health Study 2024
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI